Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil

Consultant Pharmacist

Volumn 26, Issue 2, 2011, Pages 108-110

  Rosenbloom, Michael H ^a   Brown, Jeanne ^a   Berlowitz, Dan R ^a,b   Budson, Andrew E ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Mild cognitive impairment

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DONEPEZIL; GALANTAMINE; GENERIC DRUG; MEMANTINE; NEUROLEPTIC AGENT; RIVASTIGMINE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ANOREXIA; ARTICLE; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABILITY; LEWY BODY; MAJOR CLINICAL STUDY; MEMORY DISORDER; MENTAL HEALTH; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NAUSEA; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PRETEST POSTTEST DESIGN; SIDE EFFECT; SUSTAINED DRUG RELEASE; TREATMENT DURATION; URINE INCONTINENCE; VASCULAR MILD COGNITIVE IMPAIRMENT; VOMITING; WEIGHT REDUCTION; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DEMENTIA; GALANTAMINE; HUMANS; INDANS; MIDDLE AGED; PIPERIDINES; RETROSPECTIVE STUDIES;

EID: 80051562468     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2011.108     Document Type: Article

References (6)

1. Maelicke A. Pharmacokinetic rationale for switching from donepezil to galantamine. Clin Ther 2001;23 Suppl A:8-12.
2. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-89. (Pubitemid 36995254)
3. Sadowsky CH, Farlow MR, Atkinson L et al. Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry 2005;7:43-8. (Pubitemid 41783231)
4. Sadowsky CH, Dengiz A. Olin JT et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009;24:267-75.
5. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6 month extension. The Galantamine USA 1 Study Group. Neurology 2000;54:2261-8. (Pubitemid 30416276)
6. Rasmusen L, Yan B, Robillard A et al. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther 2001;23 Suppl A:25-30.